BioSpace News Archive

Retrophin, Inc. joins the National Organization for Rare Disorders, the European Organisation for Rare Diseases, and others worldwide to recognize Rare Disease Day® 2019.

System leverages artificial intelligence and shared decision-making to improve patient care at a low financial cost

Abpro eligible to receive up to $4 billion, including $60 million in near-term R&D funding, plus potential milestones and royalties

NOXXON Pharma N.V. announced that the company will present the latest safety, survival and more mature clinical data in patients treated with the CXCL12 inhibitor NOX-A12 in combination with Merck & Co./MSD’s PD-1 inhibitor Keytruda® in metastatic, microsatellite stable pancreatic and colorectal cancer patients.

Contributing Further to Patients With Mycetoma, a Neglected Tropical Disease

MorphoSys AG announced that its licensee Janssen Research & Development, LLC, has reported that the U.S. Food and Drug Administration has approved Tremfya One-Press, a single-dose, patient-controlled injector for adults with moderate-to-severe plaque psoriasis.

NOXXON Pharma N.V. announced that it has filed the clinical trial application (CTA) with the Federal Institute for Drugs and Medical Devices, to start a Phase 1/2 clinical trial combining NOX-A12 with radiotherapy to treat newly diagnosed brain cancer patients who would not benefit from the current standard of care and whose tumor cannot be fully resected by surgery.

GENFIT, a late-stage biopharmaceutical company dedicated to the discovery and development of innovative therapeutic and diagnostic solutions in metabolic and liver related diseases, announces the filing of its 2018 Registration Document with the Autorité des marchés financiers.

Evaluate recently published the Vantage Pharma, Biotech and Medtech 2018 in review report. The annual report offers insights into the previous year’s activities in biopharma and the medical device industry.

Loos, France-based Genfit announced it is planning an initial public offering (IPO) to raise $100 million. Genfit is a late-stage biopharma company focused on developing therapeutics for metabolic and liver diseases. The area that has the most interest is nonalcoholic steatohepatitis, or NASH.